1 March 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
BACKGROUND: Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer. But ADTs with orchiectomy and gonadotropin-releasing hormone (GnRH) agonist are associated with increased risk of cardiovascular diseases, which appears less significant with GnRH antagonist. The difference of follicle-stimulating hormone (FSH) in ADT modalities is hypothesized to be responsible for ADT-associated cardiovascular diseases. METHODS: We administered orchiectomy, GnRH agonist, or GnRH antagonist in male ApoE
−/−
mice fed with Western diet and manipulated FSH levels by testosterone and FSH supplementation or FSH antibody to investigate the role of FSH elevation on atherosclerosis. By combining lipidomics, in vitro study, and intraluminal FSHR (FSH receptor) inhibition, we delineated the effects of FSH on endothelium and monocytes and the underlying mechanisms. RESULTS: Orchiectomy and GnRH agonist, but not GnRH antagonist, induced long- or short-term FSH elevation and significantly accelerated atherogenesis. In orchiectomized and testosterone-supplemented mice, FSH exposure increased atherosclerosis. In GnRH agonist–treated mice, blocking of short FSH surge by anti-FSHβ antibody greatly alleviated endothelial inflammation and delayed atherogenesis. In GnRH antagonist–treated mice, FSH supplementation aggravated atherogenesis. Mechanistically, FSH, synergizing with TNF-α (tumor necrosis factor alpha), exacerbated endothelial inflammation by elevating VCAM-1 (vascular cell adhesion protein 1) expression through the cAMP/PKA (protein kinase A)/CREB (cAMP response element-binding protein)/c-Jun and PI3K (phosphatidylinositol 3 kinase)/AKT (protein kinase B)/GSK-3β (glycogen synthase kinase 3 beta)/GATA-6 (GATA-binding protein 6) pathways. In monocytes, FSH upregulated CD29 (cluster of differentiation 29) expression via the PI3K/AKT/GSK-3β/SP1 (specificity protein 1) pathway and promoted monocyte-endothelial adhesion both in vitro and in vivo. Importantly, FSHR knockdown by shRNA in endothelium of carotid arteries markedly reduced GnRH agonist–induced endothelial inflammation and atherosclerosis in mice. CONCLUSIONS: FSH is responsible for ADT-associated atherosclerosis by exaggerating endothelial inflammation and promoting monocyte-endothelial adhesion.
29 October 2026 in Circulation Research
BACKGROUND: Chronic kidney disease (CKD) increases cardiovascular risk and is linked to arterial stiffening and atherosclerosis. How stiffness promotes atherogenesis remains unclear. DDR1 (discoidin domain receptor 1), a mechanosensory tyrosine kinase receptor, has been implicated in force-regulated arterial remodeling. We investigated whether DDR1-mediated mechanosensation links arterial stiffness to vascular smooth muscle cell (SMC)-endothelial paracrine communication in CKD-related atherosclerosis. METHODS: Single-cell RNA sequencing, secretome proteomics, and bulk RNA sequencing were integrated with stiffness-controlled models, endothelial assays, and a CKD-hyperlipidemia mouse model. SMC-specific Ddr1 deletion and a DDR1 dephosphorylation-targeting chimera (DEPTAC) were evaluated in vivo. Plasma TSP-1 (thrombospondin-1) levels were quantified in a CKD clinical cohort and analyzed in relation to renal function and atherosclerosis severity. RESULTS: CKD-associated vascular stiffening coincided with SMC phenotypic switching and enhanced THBS signaling. Multiomics integration identified THBS1 as a stiffness-induced SMC secretory effector. Stiff matrices increased SMC THBS1 secretion, promoting endothelial proliferation, migration, and leukocyte adhesion; these effects were attenuated by THBS1 knockdown. DDR1 coupled matrix stiffness cues to THBS1 expression by regulating its transcription via a tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon-FOXO3 (forkhead box O3) axis. Vascular SMC-specific Ddr1 deletion reduced aortic THBS1 levels, vascular stiffening, and atherosclerotic burden. DEPTAC suppressed aberrant DDR1 phosphorylation, reduced THBS1, and ameliorated vascular stiffening and atherosclerosis. Plasma THBS1 increased with CKD severity and correlated with atherosclerosis. CONCLUSIONS: DDR1-dependent mechanosensing in SMCs drives stiffness-induced paracrine signaling to endothelium via THBS1, promoting CKD-accelerated atherosclerosis. Targeting mechanical DDR1 activation may be therapeutic.